Member Info for Fruitsnveg

Such a joke that you were coming out with this nugget in January:

"Wake up to £10 tomorrow"

Sounding well rampy there Joshy. Not what any real investor would be pushing.

Yawn. Move on DocDan. You’ll wear out the Olivetti ribbon.

All these big pharmas with their know-it-all never fail management teams, world-beating scientific expertise, colossal budgets, innovative platforms and unparalleled political clout...and yet these crackers are littering my inbox!?

"Bristol Myers reveals trial failure"

"Another attempt at improving upon AstraZeneca’s Imfinzi in stage 3, unresectable non-small cell lung cancer (NSCLC) has gone up in flames."

"AstraZeneca’s Evusheld fails to improve Covid outcomes in Phase III trial"

"AstraZeneca's drug suffered a pair of late-stage trial failures "

"Bayer's blood thinner fails Eliquis test, sinking phase 3 trial and denting $5B sales forecast"

"Merck KGaA's BTK drug flunks pivotal multiple sclerosis trials, sending shockwaves through the sector."

"Bayer to withdraw follicular lymphoma therapy after trial failure"

"Sanofi to end tusamitamab ravtansine development after trial failure"

"GSK's blood cancer drug fails"

"Pfizer, J&J scrap Alzheimer's studies as drug fails"

"Coronavirus drug remdesivir 'fails first trial'

We can all read the headlines and they don't lie; BP is as constrained as we are. Your jolly hockey sticks comparison of "little twee inept Synairgen can't compete with Big Mighty pharma", is silly and it's fast becoming a bit of a joke DocDan, as are you.

OK Karen.

Monk doesn’t stand on a podium first of all. Thematic Poster Sessions include related abstracts which are presented in a poster format. Posters are arranged together under one or several themes. They are given a specific time period to be present at their posters, when viewers can discuss the work with them on a one-on-one or small group basis.

Synairgen’s new data will tie in and align to other research. They will share some common area/clinical need/theme. Multiple facilitators will be assigned to each thematic poster session. Facilitators have expertise in the theme being presented. They will facilitate discussions. The aim of ATS 24 is to highlight key research and themes in respiratory medicine. I know you think you know more than the experts and have spent most of today poo pooing the company’s poster presentation because you don’t understand its value and relevance. But they do. And that’s what matters.

Al part of the greater plan no doubt.

They had to submit their thematic poster presentation for evaluation /acceptance by the organisers in advance of the decision being made, which was January. I'd estimate they would have had to submit by a deadline by sometime in H2 2023. This would have been planned and within existing budget, not a last minute folly jolly.

Not off topic at all Mani. It’s DocDans favourite subject; pitting the notion of mighty pharma against the pitiful helpless biotech. Yes they are being sued and will lose billions in vaccine revenue. They may want to look for another candidate to fill the billion dollar revenue void….

I’m ambivalent about the godly status you attach to BP. I will say that I don’t necessarily see BP the sole conduit to eventual drug approval. Collaborations take many forms. AZ had their chance, great if they want another one, fabulous. But they are not the only pony in the show ring.

“ A big competent pharma would have seen this straight after Sprinter and set up new trials with much tighter inclusion criteria for a still very large cohort of patients. ”

You mean like your pharma crush AZ? Who did exactly the opposite when they had the drug. Yes, I forgot that stunning display of persistence and speed. It was so unmemorabke because it never actually happened.

I’m sure Sakura the fake scientist agrees with you DocDan. I’ll park it there so you can both bask in the glory of your own witless bla bla.

You can’t halt the march of progress toward SNG001 eventually getting approved, try as you may, so continue with the nitpickery if you wish. Synairgen will have its day, with or without you.

What’s embarrassing is your belief that you know more than representatives from BARDA, clinicians in the field and pulmonary specialists. More than the highly qualified ATS science folk who accepted Monk’s new data, to be presented to members at ATS24. There they go not knowing their own job or how to interpret the nuances of the data, not having a clue about clinical trial design. If only they’d consulted Dr-know-it-All.

Tik tok might be a better platform for your acting skills. This charade isn’t working.

Another boringly predictable takedown of the company. I wonderd how long it would take you to find an angle of attack.

I'm sure there's an enterprise who could do with your stunning level of proven scientific expertise, not to mention an injection of your know-it-all-ism, but it looks like Synairgen are doing just fine DocDan. Maybe the ATS members attending next week's conference are so dumb they haven't figured out what you have? THat they accepted a thematic poster presentation of inconsequential failed fairy dust. I hear there are typically in the region of 14,000 visitors to the conference - I'm sure one of them will concur with your stunning expose of just how bad the company is, what a failure it will only ever be, how you could have done it SO much better, and what a no hope drug they have.

-> YAWN.

". Of the patients with a lower BMI(< 30) 21/179 (11.7%) progressed, whereas

of the patients with a higher BMI(≥ 30) 24/130 (18.5%) progressed."

When was this level of granularity around BMI (above) been presented previously? This is new data.

Gives a false reason to blame the company "because of " promoted narratives. . ...is what I meant to say.

I'd be cautious about trying to pin the tale on the donkey trying to figure out what type of deal or set of next steps might emerge, it only sets up for disappointment and drives negative sentiment, gives a false reason to blame the company promoted narratives. There are many roads to Rome. Today's news is a positive signal IMHO. Keep the end goal in mind, because that's what's important. GLA.

This analysis is new. It's what I would expect to precede clinical trials. The ducks are lined up.

This analysis is new. It's what I would expect to precede clinical trials.

TP,

So if I understand you correctly, if a route through to approval of SNG001 is found (cost and logistics aside as we know it's going to cost and we know there are unavoidable steps to making that happen), you would be happy?

Incorrect. The company did not attend conference in Edinburgh this year.